medigraphic.com
ISSN 1025-0255 (Electronic)

2013, Number 1

<< Back Next >>

AMC 2013; 17 (1)

Characterization of metabolic syndrome in women with clinical hypothyroidism

Sarmiento TY, Miguel SPE, Almaguer HA, García NLA, Mariño SAL, Edwards SI

Language: Spanish
References: 28
Page: 51-64
PDF size: 285.89 Kb.


ABSTRACT

Background: metabolic syndrome comprises a set of risk factors characterized by visceral obesity, dyslipidemia, elevated numbers of blood pressure, insulin resistance with or without alterations of blood glucose and a proinflammatory and prothrombotic state, favoring the occurrence of type II diabetes mellitus and cardiovascular disease. Objetive: to characterize female patients with metabolic syndrome and clinical hypothyroidism through clinical, laboratory, and anthropometric variables. Method: a crosssectional study in women with clinical hypothyroidism belonging to the health areas in Holguin municipality was performed from January to March 2010. Analysis of variance to compare quantitative variables was used as well as chisquared or Fisher´s exact test for the association among qualitative variables in the statistical package SPSS, with the 0.05 significance level. Results: according to the National Cholesterol Education Program criteria, 37 women carriers of metabolic syndrome were detected among 85 women with clinical hypothyroidism, for a 43,5 %. Patients with metabolic syndrome showed higher values of age, body weight, body mass index, abdominal circumference, hip circumference, systolic and diastolic blood pressure, blood glucose, uric acid, triglycerides, cholesterol, low density lipoprotein, total cholesterol/high density lipoprotein ratio and the relation between low density lipoprotein/high density lipoprotein, with a significant reduction in high density lipoprotein cholesterol. Conclusions: it is important the diagnosis of metabolic syndrome in patients with clinical hypothyroidism by the high frequency of associated comorbidity and a better characterization of patients.


REFERENCES

  1. Johnson LW, Weinstock RS. The Metabolic Syndrome: Concepts and Controversy. Mayo Clin Proc. 2006;81(12):161520.

  2. American Diabetes Association. Standards of medical care in diabetes2008. Diabetes Care. 2008;31(Suppl 1):S1254.

  3. Peppa M, Koliaki C, Nikolopoulos P, Raptis SA. Skeletal Muscle Insulin Resistance in Endocrine Disease. J Biomed Biotechnol [Internet]. 2010 [citado 16 Sep 2011];2010:[aprox. 13 p.]. Disponible en: http://preview.ncbi.nlm.nih.gov/pmc/articles/PMC2840413/.

  4. KyungHyun C. Biomedicinal implications of highdensity lipoprotein: its composition, structure, functions, and clinical applications. BMB reports. 2009;42(7):393400.

  5. Miguel Soca PE. Dislipidemias. Acimed [Internet]. 2009 [citado 10 Sep 2011];20(6):[aprox. 9 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S102494352009001200012& lng=es&nrm=iso&tlng=es.

  6. Noa Cordero SS, Noa Arias M, Legón Morgado Y. Hipotiroidismo. Sus efectos sobre la salud. MediCiego [Internet]. 2007 [citado 2 Sep 2011];13(2):[aprox. 8 p.]. Disponible en: http://bvs.sld.cu/revistas/mciego/vol13_02_07/revisiones/r2_v13_0207.htm.

  7. García D, Barassi C, Acuña A, Bozzo S. Aspectos clínicos fundamentales del hipotiroidismo Clínico. Bol Hosp San Juan de Dios. 2005;52(4):21222.

  8. Fink HJ, Hintze G. Current thyroid diagnostics and therapy in disorders of fertility and in pregnancy. Med Klin (Munich). 2006;101(8):64552.

  9. Navarro Despaigne D. Epidemiología de las enfermedades del tiroides en Cuba. Rev Cubana Endocrinol. 2006;15(1):1925.

  10. Demidova T, Galieva OR. The role of thyroid hypofunction in development of metabolic syndrome. Ter Arkh. 2009;81(4):6973.

  11. Shantha GPS, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, et al. Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross–sectional study from South India. Thyroid Research [Internet]. 2009 [citado 8 Sep 2011];2(2):[aprox. 7 p.]. Disponible en: http://www.thyroidresearchjournal.com/content/2/1/2.

  12. WHO/ IDF consultation. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Ginebra: World Health Organization. International Diabetes Federation; 2006.

  13. Comisión Nacional Técnica Asesora del Programa de Hipertensión Arterial. Hipertensión arterial. Guía para la prevención, diagnóstico y tratamiento. La Habana: Editorial Ciencias Médicas; 2008.

  14. GarduñoGarcia JJ, AlvirdeGarcia U, LópezCarrasco G, Padilla Mendoza ME, Mehta R, ArellanoCampos O, et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol. 2010;163(2):2738.

  15. Erdogan M, Canataroglu A, Ganidagli S, Kulaksýzoglu M. Metabolic syndrome prevalence in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters. J Endocrinol Invest. 2011 JulAug;34( 7):48892.

  16. Kiya Y, Miura S. Effect of levothyroxine on total lipid profiles in patients with hypothyroidism. Endocrinol J. 2006;53(6):8658.

  17. Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW, et al. Enhanced Cellular Uptake of Remnant HighDensity Lipoprotein Particles: A Mechanism for High Density Lipoprotein Lowering in Insulin Resistance and Hypertriglyceridemia. Circ Res. 2008;103:15966.

  18. Miguel Soca PE. El síndrome metabólico: un alto riesgo para individuos sedentarios. ACIMED [Internet]. 2009 [citado 8 Ago 2011];20(2):[aprox. 8 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_issuetoc&pid=1024943520090008& lng=es&nrm=iso.

  19. Miguel Soca PE, Cruz Torres W, González Ferrer J, Cardona Cáceres X, Cruz Lage LA, Hernández Tamayo M. Efectos beneficiosos de cambios en la dieta y ejercicios físicos en mujeres obesas con síndrome metabólico. Rev Pan Cuba Sal. 2009;4(3):2936.

  20. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008;14(34): 22231.

  21. Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, et al. Insulin Action in Adipose Tissue and Muscle in Hypothyroidism. J Clin Endocrinol Metab. 2006;91(12):49307.

  22. Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009;160(5):78590.

  23. Miguel Soca PE, Sarmiento Teruel Y. Hipertensión arterial, un enemigo peligroso. Acimed [Internet]. 2009 [citado 8 Oct 2011];20(3):[aprox. 9 p.]. Disponible en: http://www.bvs.sld.cu/revistas/aci/vol20_3_09/aci07909.htm.

  24. Francischetti EA, Celoria BMJ , Francischetti A, Genelhu VA. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Rev Cardiovasc Ther. 2008;6(3):289303.

  25. Garkunova LV, Ametov AS. Comparative assessment of efficacy of hypotensive drugs from various groups and angiotensin converting enzyme inhibitors in patients with hypothyroidism and hypertension. Kardiologiia. 2005;45(9):7980.

  26. Ferns G, Keti V. HDLcholesterol modulation and its impact on the management of cardiovascular risk. Ann Clin Biochem. 2008;45:1228.

  27. Egorov VS, Sviridenko NI, Platonova NM, Arbuzova MI, Zlotnikova OA, Buziashvili IuI, et al. Disturbances of thyroid function after coronary angiography. Kardiologia. 2006;46(4):469.

  28. CharltonMenys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2010;93:2742.




2020     |     www.medigraphic.com